nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefloquine—HBA1—sarcoma	0.676	1	CbGaD
Mefloquine—HBA1—Effects of Nitric Oxide—MB—sarcoma	0.0236	0.407	CbGpPWpGaD
Mefloquine—CYP3A4—Thiotepa—sarcoma	0.02	0.191	CbGbCtD
Mefloquine—ABCB1—Dactinomycin—sarcoma	0.0161	0.153	CbGbCtD
Mefloquine—ABCB1—Mitoxantrone—sarcoma	0.0144	0.137	CbGbCtD
Mefloquine—HBA2—Erythrocytes take up carbon dioxide and release oxygen—HBA1—sarcoma	0.0102	0.176	CbGpPWpGaD
Mefloquine—ABCB1—Vincristine—sarcoma	0.00988	0.0941	CbGbCtD
Mefloquine—ABCB1—Etoposide—sarcoma	0.00906	0.0862	CbGbCtD
Mefloquine—HBA2—dermis—sarcoma	0.00868	0.108	CbGeAlD
Mefloquine—CYP3A4—Mitoxantrone—sarcoma	0.00861	0.0819	CbGbCtD
Mefloquine—HBA2—Scavenging of heme from plasma—HBA1—sarcoma	0.00762	0.131	CbGpPWpGaD
Mefloquine—HBA1—forelimb—sarcoma	0.00619	0.0773	CbGeAlD
Mefloquine—ABCB1—Doxorubicin—sarcoma	0.00618	0.0588	CbGbCtD
Mefloquine—CYP3A4—Vincristine—sarcoma	0.00592	0.0564	CbGbCtD
Mefloquine—CYP2D6—Doxorubicin—sarcoma	0.00582	0.0554	CbGbCtD
Mefloquine—HBA2—leg—sarcoma	0.00573	0.0715	CbGeAlD
Mefloquine—HBA2—forelimb—sarcoma	0.00568	0.071	CbGeAlD
Mefloquine—HBA1—hindlimb—sarcoma	0.00557	0.0695	CbGeAlD
Mefloquine—CYP3A4—Etoposide—sarcoma	0.00543	0.0517	CbGbCtD
Mefloquine—HBA2—hindlimb—sarcoma	0.00511	0.0638	CbGeAlD
Mefloquine—HBA1—appendage—sarcoma	0.00478	0.0597	CbGeAlD
Mefloquine—HBA2—appendage—sarcoma	0.00439	0.0548	CbGeAlD
Mefloquine—CYP3A4—Doxorubicin—sarcoma	0.0037	0.0352	CbGbCtD
Mefloquine—HBA2—Binding and Uptake of Ligands by Scavenger Receptors—HBA1—sarcoma	0.00304	0.0523	CbGpPWpGaD
Mefloquine—BCHE—diaphragm—sarcoma	0.00273	0.0341	CbGeAlD
Mefloquine—HBA2—endothelium—sarcoma	0.00265	0.0331	CbGeAlD
Mefloquine—HBA2—embryo—sarcoma	0.00146	0.0182	CbGeAlD
Mefloquine—HBA1—hematopoietic system—sarcoma	0.00142	0.0177	CbGeAlD
Mefloquine—HBA1—connective tissue—sarcoma	0.00136	0.017	CbGeAlD
Mefloquine—HBA2—hematopoietic system—sarcoma	0.0013	0.0162	CbGeAlD
Mefloquine—HBA2—connective tissue—sarcoma	0.00125	0.0156	CbGeAlD
Mefloquine—HBA1—skin of body—sarcoma	0.00123	0.0154	CbGeAlD
Mefloquine—HBA2—smooth muscle tissue—sarcoma	0.00115	0.0143	CbGeAlD
Mefloquine—HBA2—skin of body—sarcoma	0.00113	0.0141	CbGeAlD
Mefloquine—HBA1—lymphoid tissue—sarcoma	0.000997	0.0124	CbGeAlD
Mefloquine—HBA2—lymphoid tissue—sarcoma	0.000915	0.0114	CbGeAlD
Mefloquine—HBA1—bone marrow—sarcoma	0.000908	0.0113	CbGeAlD
Mefloquine—CYP19A1—Ovarian Infertility Genes—GJA4—sarcoma	0.000862	0.0148	CbGpPWpGaD
Mefloquine—HBA2—bone marrow—sarcoma	0.000834	0.0104	CbGeAlD
Mefloquine—HBA1—testis—sarcoma	0.000776	0.00969	CbGeAlD
Mefloquine—HBA1—liver—sarcoma	0.000734	0.00916	CbGeAlD
Mefloquine—HBA2—testis—sarcoma	0.000713	0.0089	CbGeAlD
Mefloquine—ADORA2A—hematopoietic system—sarcoma	0.000677	0.00845	CbGeAlD
Mefloquine—HBA2—liver—sarcoma	0.000674	0.00841	CbGeAlD
Mefloquine—ADORA2A—HIF-2-alpha transcription factor network—FLT1—sarcoma	0.000585	0.0101	CbGpPWpGaD
Mefloquine—ADORA1—hematopoietic system—sarcoma	0.000584	0.0073	CbGeAlD
Mefloquine—HBA1—lymph node—sarcoma	0.000563	0.00702	CbGeAlD
Mefloquine—HBA2—lymph node—sarcoma	0.000517	0.00645	CbGeAlD
Mefloquine—HBA1—Folate Metabolism—IL2—sarcoma	0.000511	0.0088	CbGpPWpGaD
Mefloquine—ADORA2A—lymphoid tissue—sarcoma	0.000477	0.00595	CbGeAlD
Mefloquine—ADORA1—cardiac atrium—sarcoma	0.000444	0.00554	CbGeAlD
Mefloquine—CYP19A1—hematopoietic system—sarcoma	0.000396	0.00495	CbGeAlD
Mefloquine—ADORA1—tendon—sarcoma	0.000387	0.00483	CbGeAlD
Mefloquine—ACHE—tendon—sarcoma	0.000384	0.0048	CbGeAlD
Mefloquine—CYP19A1—connective tissue—sarcoma	0.000382	0.00476	CbGeAlD
Mefloquine—ADORA2A—testis—sarcoma	0.000371	0.00463	CbGeAlD
Mefloquine—ACHE—Melatonin metabolism and effects—FOXO1—sarcoma	0.00037	0.00637	CbGpPWpGaD
Mefloquine—CYP19A1—FSH signaling pathway—FOXO1—sarcoma	0.00036	0.0062	CbGpPWpGaD
Mefloquine—ADORA2A—liver—sarcoma	0.000351	0.00438	CbGeAlD
Mefloquine—ADORA2A—HIF-2-alpha transcription factor network—KDR—sarcoma	0.000337	0.00581	CbGpPWpGaD
Mefloquine—BCHE—myometrium—sarcoma	0.000332	0.00415	CbGeAlD
Mefloquine—HBA1—Folate Metabolism—TP53—sarcoma	0.000328	0.00565	CbGpPWpGaD
Mefloquine—ADORA1—testis—sarcoma	0.00032	0.004	CbGeAlD
Mefloquine—ACHE—testis—sarcoma	0.000318	0.00397	CbGeAlD
Mefloquine—BCHE—seminal vesicle—sarcoma	0.0003	0.00375	CbGeAlD
Mefloquine—CYP19A1—uterus—sarcoma	0.000299	0.00374	CbGeAlD
Mefloquine—BCHE—hematopoietic system—sarcoma	0.000285	0.00356	CbGeAlD
Mefloquine—CYP19A1—FSH signaling pathway—CREB1—sarcoma	0.000261	0.0045	CbGpPWpGaD
Mefloquine—BCHE—smooth muscle tissue—sarcoma	0.000251	0.00314	CbGeAlD
Mefloquine—BCHE—skin of body—sarcoma	0.000248	0.0031	CbGeAlD
Mefloquine—ADORA1—lymph node—sarcoma	0.000232	0.0029	CbGeAlD
Mefloquine—ACHE—lymph node—sarcoma	0.000231	0.00288	CbGeAlD
Mefloquine—CYP19A1—testis—sarcoma	0.000217	0.00271	CbGeAlD
Mefloquine—BCHE—cardiac atrium—sarcoma	0.000217	0.00271	CbGeAlD
Mefloquine—BCHE—uterus—sarcoma	0.000216	0.00269	CbGeAlD
Mefloquine—ACHE—ATF-2 transcription factor network—PDGFRA—sarcoma	0.000206	0.00355	CbGpPWpGaD
Mefloquine—CYP19A1—liver—sarcoma	0.000205	0.00256	CbGeAlD
Mefloquine—CYP3A4—hematopoietic system—sarcoma	0.000192	0.0024	CbGeAlD
Mefloquine—CYP2D6—hematopoietic system—sarcoma	0.000189	0.00236	CbGeAlD
Mefloquine—ADORA2A—HIF-2-alpha transcription factor network—VEGFA—sarcoma	0.000186	0.0032	CbGpPWpGaD
Mefloquine—BCHE—bone marrow—sarcoma	0.000183	0.00228	CbGeAlD
Mefloquine—CYP19A1—FSH signaling pathway—SRC—sarcoma	0.000168	0.0029	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—ENO2—sarcoma	0.000166	0.00286	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—HBA1—sarcoma	0.000165	0.00284	CbGpPWpGaD
Mefloquine—ABCB1—HIF-1-alpha transcription factor network—NPM1—sarcoma	0.00016	0.00275	CbGpPWpGaD
Mefloquine—ABCB1—myometrium—sarcoma	0.000158	0.00198	CbGeAlD
Mefloquine—CYP19A1—lymph node—sarcoma	0.000157	0.00197	CbGeAlD
Mefloquine—BCHE—testis—sarcoma	0.000156	0.00195	CbGeAlD
Mefloquine—ABCB1—embryo—sarcoma	0.000152	0.0019	CbGeAlD
Mefloquine—ADORA1—G alpha (i) signalling events—CXCR4—sarcoma	0.000152	0.00262	CbGpPWpGaD
Mefloquine—ACHE—ATF-2 transcription factor network—CREB1—sarcoma	0.000152	0.00262	CbGpPWpGaD
Mefloquine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—sarcoma	0.000152	0.00261	CbGpPWpGaD
Mefloquine—CYP2D6—Melatonin metabolism and effects—FOXO1—sarcoma	0.000152	0.00261	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000152	0.00261	CbGpPWpGaD
Mefloquine—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000149	0.00256	CbGpPWpGaD
Mefloquine—BCHE—liver—sarcoma	0.000148	0.00185	CbGeAlD
Mefloquine—ABCB1—seminal vesicle—sarcoma	0.000143	0.00179	CbGeAlD
Mefloquine—ACHE—ATF-2 transcription factor network—MMP2—sarcoma	0.000142	0.00244	CbGpPWpGaD
Mefloquine—ADORA1—GPCRs, Class A Rhodopsin-like—CXCR4—sarcoma	0.000141	0.00243	CbGpPWpGaD
Mefloquine—CYP19A1—Tryptophan metabolism—MDM2—sarcoma	0.000141	0.00243	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—PLCG1—sarcoma	0.000141	0.00243	CbGpPWpGaD
Mefloquine—Paraesthesia—Vincristine—sarcoma	0.000139	0.00172	CcSEcCtD
Mefloquine—Urticaria—Thiotepa—sarcoma	0.000139	0.00171	CcSEcCtD
Mefloquine—Malaise—Etoposide—sarcoma	0.000139	0.00171	CcSEcCtD
Mefloquine—Dermatitis bullous—Doxorubicin—sarcoma	0.000139	0.00171	CcSEcCtD
Mefloquine—Vertigo—Etoposide—sarcoma	0.000138	0.00171	CcSEcCtD
Mefloquine—Abdominal pain—Thiotepa—sarcoma	0.000138	0.00171	CcSEcCtD
Mefloquine—Body temperature increased—Thiotepa—sarcoma	0.000138	0.00171	CcSEcCtD
Mefloquine—Leukopenia—Etoposide—sarcoma	0.000138	0.0017	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.000137	0.0017	CcSEcCtD
Mefloquine—Body temperature increased—Dactinomycin—sarcoma	0.000137	0.00169	CcSEcCtD
Mefloquine—Abdominal pain—Dactinomycin—sarcoma	0.000137	0.00169	CcSEcCtD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PLCG1—sarcoma	0.000136	0.00234	CbGpPWpGaD
Mefloquine—ABCB1—hematopoietic system—sarcoma	0.000136	0.0017	CbGeAlD
Mefloquine—Mood swings—Epirubicin—sarcoma	0.000136	0.00167	CcSEcCtD
Mefloquine—Paraesthesia—Mitoxantrone—sarcoma	0.000135	0.00167	CcSEcCtD
Mefloquine—Loss of consciousness—Etoposide—sarcoma	0.000135	0.00167	CcSEcCtD
Mefloquine—Decreased appetite—Vincristine—sarcoma	0.000135	0.00166	CcSEcCtD
Mefloquine—Ataxia—Epirubicin—sarcoma	0.000135	0.00166	CcSEcCtD
Mefloquine—Dyspnoea—Mitoxantrone—sarcoma	0.000134	0.00166	CcSEcCtD
Mefloquine—Somnolence—Mitoxantrone—sarcoma	0.000134	0.00166	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Vincristine—sarcoma	0.000134	0.00165	CcSEcCtD
Mefloquine—Fatigue—Vincristine—sarcoma	0.000134	0.00165	CcSEcCtD
Mefloquine—Convulsion—Etoposide—sarcoma	0.000133	0.00165	CcSEcCtD
Mefloquine—Dyspepsia—Mitoxantrone—sarcoma	0.000133	0.00164	CcSEcCtD
Mefloquine—Hypertension—Etoposide—sarcoma	0.000133	0.00164	CcSEcCtD
Mefloquine—Decreased appetite—Mitoxantrone—sarcoma	0.000131	0.00162	CcSEcCtD
Mefloquine—Chest pain—Etoposide—sarcoma	0.000131	0.00162	CcSEcCtD
Mefloquine—Affect lability—Doxorubicin—sarcoma	0.00013	0.00161	CcSEcCtD
Mefloquine—Fatigue—Mitoxantrone—sarcoma	0.00013	0.00161	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.00013	0.00161	CcSEcCtD
Mefloquine—Discomfort—Etoposide—sarcoma	0.000129	0.0016	CcSEcCtD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—ATF1—sarcoma	0.000129	0.00223	CbGpPWpGaD
Mefloquine—Hypersensitivity—Thiotepa—sarcoma	0.000129	0.00159	CcSEcCtD
Mefloquine—Hypersensitivity—Dactinomycin—sarcoma	0.000128	0.00158	CcSEcCtD
Mefloquine—Gastrointestinal pain—Vincristine—sarcoma	0.000127	0.00156	CcSEcCtD
Mefloquine—Confusional state—Etoposide—sarcoma	0.000126	0.00156	CcSEcCtD
Mefloquine—Muscular weakness—Epirubicin—sarcoma	0.000126	0.00156	CcSEcCtD
Mefloquine—HBA1—Metabolism—ENO2—sarcoma	0.000126	0.00217	CbGpPWpGaD
Mefloquine—Anaphylactic shock—Etoposide—sarcoma	0.000125	0.00155	CcSEcCtD
Mefloquine—Mood swings—Doxorubicin—sarcoma	0.000125	0.00155	CcSEcCtD
Mefloquine—Asthenia—Thiotepa—sarcoma	0.000125	0.00155	CcSEcCtD
Mefloquine—Ataxia—Doxorubicin—sarcoma	0.000124	0.00154	CcSEcCtD
Mefloquine—Asthenia—Dactinomycin—sarcoma	0.000124	0.00154	CcSEcCtD
Mefloquine—Feeling abnormal—Mitoxantrone—sarcoma	0.000124	0.00154	CcSEcCtD
Mefloquine—Pruritus—Thiotepa—sarcoma	0.000124	0.00153	CcSEcCtD
Mefloquine—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000123	0.00152	CcSEcCtD
Mefloquine—Thrombocytopenia—Etoposide—sarcoma	0.000123	0.00152	CcSEcCtD
Mefloquine—Tachycardia—Etoposide—sarcoma	0.000122	0.00151	CcSEcCtD
Mefloquine—Body temperature increased—Vincristine—sarcoma	0.000122	0.00151	CcSEcCtD
Mefloquine—Abdominal pain—Vincristine—sarcoma	0.000122	0.00151	CcSEcCtD
Mefloquine—Skin disorder—Etoposide—sarcoma	0.000122	0.00151	CcSEcCtD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—ATF1—sarcoma	0.000122	0.00209	CbGpPWpGaD
Mefloquine—Hyperhidrosis—Etoposide—sarcoma	0.000121	0.0015	CcSEcCtD
Mefloquine—ADORA1—Class A/1 (Rhodopsin-like receptors)—CXCR4—sarcoma	0.000121	0.00209	CbGpPWpGaD
Mefloquine—Urticaria—Mitoxantrone—sarcoma	0.00012	0.00148	CcSEcCtD
Mefloquine—Diarrhoea—Thiotepa—sarcoma	0.000119	0.00148	CcSEcCtD
Mefloquine—Abdominal pain—Mitoxantrone—sarcoma	0.000119	0.00147	CcSEcCtD
Mefloquine—Body temperature increased—Mitoxantrone—sarcoma	0.000119	0.00147	CcSEcCtD
Mefloquine—Diarrhoea—Dactinomycin—sarcoma	0.000119	0.00147	CcSEcCtD
Mefloquine—Hypotension—Etoposide—sarcoma	0.000117	0.00145	CcSEcCtD
Mefloquine—Muscular weakness—Doxorubicin—sarcoma	0.000117	0.00144	CcSEcCtD
Mefloquine—Dizziness—Thiotepa—sarcoma	0.000115	0.00143	CcSEcCtD
Mefloquine—Hypersensitivity—Vincristine—sarcoma	0.000114	0.00141	CcSEcCtD
Mefloquine—BCHE—lymph node—sarcoma	0.000113	0.00142	CbGeAlD
Mefloquine—ABCB1—HIF-1-alpha transcription factor network—CXCR4—sarcoma	0.000113	0.00194	CbGpPWpGaD
Mefloquine—Paraesthesia—Etoposide—sarcoma	0.000113	0.00139	CcSEcCtD
Mefloquine—Dyspnoea—Etoposide—sarcoma	0.000112	0.00138	CcSEcCtD
Mefloquine—Somnolence—Etoposide—sarcoma	0.000112	0.00138	CcSEcCtD
Mefloquine—Hypersensitivity—Mitoxantrone—sarcoma	0.000111	0.00137	CcSEcCtD
Mefloquine—Asthenia—Vincristine—sarcoma	0.000111	0.00137	CcSEcCtD
Mefloquine—Vomiting—Thiotepa—sarcoma	0.000111	0.00137	CcSEcCtD
Mefloquine—Pneumonia—Epirubicin—sarcoma	0.000111	0.00137	CcSEcCtD
Mefloquine—Vomiting—Dactinomycin—sarcoma	0.00011	0.00136	CcSEcCtD
Mefloquine—Rash—Thiotepa—sarcoma	0.00011	0.00136	CcSEcCtD
Mefloquine—Dermatitis—Thiotepa—sarcoma	0.00011	0.00136	CcSEcCtD
Mefloquine—ACHE—ATF-2 transcription factor network—CCND1—sarcoma	0.00011	0.00189	CbGpPWpGaD
Mefloquine—Headache—Thiotepa—sarcoma	0.000109	0.00135	CcSEcCtD
Mefloquine—ACHE—ATF-2 transcription factor network—JUN—sarcoma	0.000109	0.00188	CbGpPWpGaD
Mefloquine—Stevens-Johnson syndrome—Epirubicin—sarcoma	0.000109	0.00135	CcSEcCtD
Mefloquine—Rash—Dactinomycin—sarcoma	0.000109	0.00135	CcSEcCtD
Mefloquine—ADORA2A—GPCRs, Class A Rhodopsin-like—CXCR4—sarcoma	0.000109	0.00188	CbGpPWpGaD
Mefloquine—Decreased appetite—Etoposide—sarcoma	0.000109	0.00135	CcSEcCtD
Mefloquine—Renal failure—Epirubicin—sarcoma	0.000108	0.00134	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Etoposide—sarcoma	0.000108	0.00134	CcSEcCtD
Mefloquine—Asthenia—Mitoxantrone—sarcoma	0.000108	0.00134	CcSEcCtD
Mefloquine—Fatigue—Etoposide—sarcoma	0.000108	0.00134	CcSEcCtD
Mefloquine—Neuropathy peripheral—Epirubicin—sarcoma	0.000108	0.00134	CcSEcCtD
Mefloquine—HBA1—Metabolism—PLCG1—sarcoma	0.000107	0.00184	CbGpPWpGaD
Mefloquine—Diarrhoea—Vincristine—sarcoma	0.000106	0.00131	CcSEcCtD
Mefloquine—Sweating—Epirubicin—sarcoma	0.000106	0.00131	CcSEcCtD
Mefloquine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—sarcoma	0.000106	0.00182	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—PLCG1—sarcoma	0.000105	0.0018	CbGpPWpGaD
Mefloquine—Hepatobiliary disease—Epirubicin—sarcoma	0.000104	0.00129	CcSEcCtD
Mefloquine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—sarcoma	0.000104	0.00179	CbGpPWpGaD
Mefloquine—Nausea—Thiotepa—sarcoma	0.000104	0.00128	CcSEcCtD
Mefloquine—CYP2D6—testis—sarcoma	0.000104	0.00129	CbGeAlD
Mefloquine—Feeling abnormal—Etoposide—sarcoma	0.000103	0.00128	CcSEcCtD
Mefloquine—Diarrhoea—Mitoxantrone—sarcoma	0.000103	0.00127	CcSEcCtD
Mefloquine—Nausea—Dactinomycin—sarcoma	0.000103	0.00127	CcSEcCtD
Mefloquine—Agranulocytosis—Epirubicin—sarcoma	0.000103	0.00127	CcSEcCtD
Mefloquine—ABCB1—uterus—sarcoma	0.000103	0.00128	CbGeAlD
Mefloquine—Pneumonia—Doxorubicin—sarcoma	0.000103	0.00127	CcSEcCtD
Mefloquine—Gastrointestinal pain—Etoposide—sarcoma	0.000103	0.00127	CcSEcCtD
Mefloquine—Dizziness—Vincristine—sarcoma	0.000102	0.00127	CcSEcCtD
Mefloquine—Stevens-Johnson syndrome—Doxorubicin—sarcoma	0.000101	0.00125	CcSEcCtD
Mefloquine—Bradycardia—Epirubicin—sarcoma	0.000101	0.00124	CcSEcCtD
Mefloquine—Renal failure—Doxorubicin—sarcoma	0.0001	0.00124	CcSEcCtD
Mefloquine—Neuropathy peripheral—Doxorubicin—sarcoma	0.0001	0.00124	CcSEcCtD
Mefloquine—Urticaria—Etoposide—sarcoma	9.97e-05	0.00123	CcSEcCtD
Mefloquine—CYP3A4—liver—sarcoma	9.96e-05	0.00124	CbGeAlD
Mefloquine—ADORA2A—Signaling by NGF—ATF1—sarcoma	9.94e-05	0.00171	CbGpPWpGaD
Mefloquine—Abdominal pain—Etoposide—sarcoma	9.92e-05	0.00123	CcSEcCtD
Mefloquine—Body temperature increased—Etoposide—sarcoma	9.92e-05	0.00123	CcSEcCtD
Mefloquine—Vomiting—Vincristine—sarcoma	9.85e-05	0.00122	CcSEcCtD
Mefloquine—CYP2D6—liver—sarcoma	9.8e-05	0.00122	CbGeAlD
Mefloquine—Sweating—Doxorubicin—sarcoma	9.78e-05	0.00121	CcSEcCtD
Mefloquine—Rash—Vincristine—sarcoma	9.76e-05	0.00121	CcSEcCtD
Mefloquine—Dermatitis—Vincristine—sarcoma	9.76e-05	0.00121	CcSEcCtD
Mefloquine—Connective tissue disorder—Epirubicin—sarcoma	9.73e-05	0.0012	CcSEcCtD
Mefloquine—Headache—Vincristine—sarcoma	9.7e-05	0.0012	CcSEcCtD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—FOXO1—sarcoma	9.65e-05	0.00166	CbGpPWpGaD
Mefloquine—Hepatobiliary disease—Doxorubicin—sarcoma	9.65e-05	0.00119	CcSEcCtD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PDGFRB—sarcoma	9.64e-05	0.00166	CbGpPWpGaD
Mefloquine—Vomiting—Mitoxantrone—sarcoma	9.59e-05	0.00118	CcSEcCtD
Mefloquine—ABCB1—lymphoid tissue—sarcoma	9.58e-05	0.0012	CbGeAlD
Mefloquine—Visual impairment—Epirubicin—sarcoma	9.54e-05	0.00118	CcSEcCtD
Mefloquine—Agranulocytosis—Doxorubicin—sarcoma	9.52e-05	0.00118	CcSEcCtD
Mefloquine—Rash—Mitoxantrone—sarcoma	9.51e-05	0.00117	CcSEcCtD
Mefloquine—Dermatitis—Mitoxantrone—sarcoma	9.5e-05	0.00117	CcSEcCtD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PDGFRA—sarcoma	9.49e-05	0.00163	CbGpPWpGaD
Mefloquine—Headache—Mitoxantrone—sarcoma	9.45e-05	0.00117	CcSEcCtD
Mefloquine—Erythema multiforme—Epirubicin—sarcoma	9.36e-05	0.00116	CcSEcCtD
Mefloquine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCR4—sarcoma	9.35e-05	0.00161	CbGpPWpGaD
Mefloquine—Bradycardia—Doxorubicin—sarcoma	9.32e-05	0.00115	CcSEcCtD
Mefloquine—Eye disorder—Epirubicin—sarcoma	9.25e-05	0.00114	CcSEcCtD
Mefloquine—ADORA1—Circadian rythm related genes—CREB1—sarcoma	9.25e-05	0.00159	CbGpPWpGaD
Mefloquine—Hypersensitivity—Etoposide—sarcoma	9.24e-05	0.00114	CcSEcCtD
Mefloquine—Tinnitus—Epirubicin—sarcoma	9.23e-05	0.00114	CcSEcCtD
Mefloquine—ADORA1—GPCR ligand binding—CXCR4—sarcoma	9.23e-05	0.00159	CbGpPWpGaD
Mefloquine—Nausea—Vincristine—sarcoma	9.2e-05	0.00114	CcSEcCtD
Mefloquine—Flushing—Epirubicin—sarcoma	9.19e-05	0.00113	CcSEcCtD
Mefloquine—Cardiac disorder—Epirubicin—sarcoma	9.19e-05	0.00113	CcSEcCtD
Mefloquine—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	9.17e-05	0.00158	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—FOXO1—sarcoma	9.09e-05	0.00156	CbGpPWpGaD
Mefloquine—Asthenia—Etoposide—sarcoma	9e-05	0.00111	CcSEcCtD
Mefloquine—Connective tissue disorder—Doxorubicin—sarcoma	9e-05	0.00111	CcSEcCtD
Mefloquine—Angiopathy—Epirubicin—sarcoma	8.98e-05	0.00111	CcSEcCtD
Mefloquine—Nausea—Mitoxantrone—sarcoma	8.96e-05	0.00111	CcSEcCtD
Mefloquine—Mediastinal disorder—Epirubicin—sarcoma	8.92e-05	0.0011	CcSEcCtD
Mefloquine—Chills—Epirubicin—sarcoma	8.88e-05	0.0011	CcSEcCtD
Mefloquine—Pruritus—Etoposide—sarcoma	8.88e-05	0.0011	CcSEcCtD
Mefloquine—Visual impairment—Doxorubicin—sarcoma	8.83e-05	0.00109	CcSEcCtD
Mefloquine—Alopecia—Epirubicin—sarcoma	8.75e-05	0.00108	CcSEcCtD
Mefloquine—ABCB1—bone marrow—sarcoma	8.72e-05	0.00109	CbGeAlD
Mefloquine—Mental disorder—Epirubicin—sarcoma	8.67e-05	0.00107	CcSEcCtD
Mefloquine—Erythema multiforme—Doxorubicin—sarcoma	8.66e-05	0.00107	CcSEcCtD
Mefloquine—Erythema—Epirubicin—sarcoma	8.62e-05	0.00106	CcSEcCtD
Mefloquine—Malnutrition—Epirubicin—sarcoma	8.62e-05	0.00106	CcSEcCtD
Mefloquine—Diarrhoea—Etoposide—sarcoma	8.58e-05	0.00106	CcSEcCtD
Mefloquine—Eye disorder—Doxorubicin—sarcoma	8.56e-05	0.00106	CcSEcCtD
Mefloquine—Tinnitus—Doxorubicin—sarcoma	8.54e-05	0.00106	CcSEcCtD
Mefloquine—Flushing—Doxorubicin—sarcoma	8.5e-05	0.00105	CcSEcCtD
Mefloquine—Cardiac disorder—Doxorubicin—sarcoma	8.5e-05	0.00105	CcSEcCtD
Mefloquine—Angiopathy—Doxorubicin—sarcoma	8.31e-05	0.00103	CcSEcCtD
Mefloquine—Dizziness—Etoposide—sarcoma	8.3e-05	0.00102	CcSEcCtD
Mefloquine—Muscle spasms—Epirubicin—sarcoma	8.28e-05	0.00102	CcSEcCtD
Mefloquine—Mediastinal disorder—Doxorubicin—sarcoma	8.25e-05	0.00102	CcSEcCtD
Mefloquine—Chills—Doxorubicin—sarcoma	8.22e-05	0.00102	CcSEcCtD
Mefloquine—Vision blurred—Epirubicin—sarcoma	8.12e-05	0.001	CcSEcCtD
Mefloquine—ACHE—Peptide hormone metabolism—CTNNB1—sarcoma	8.1e-05	0.0014	CbGpPWpGaD
Mefloquine—Alopecia—Doxorubicin—sarcoma	8.09e-05	0.001	CcSEcCtD
Mefloquine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—sarcoma	8.07e-05	0.00139	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	8.05e-05	0.00139	CbGpPWpGaD
Mefloquine—Mental disorder—Doxorubicin—sarcoma	8.02e-05	0.000991	CcSEcCtD
Mefloquine—Ill-defined disorder—Epirubicin—sarcoma	7.99e-05	0.000988	CcSEcCtD
Mefloquine—Vomiting—Etoposide—sarcoma	7.98e-05	0.000986	CcSEcCtD
Mefloquine—Malnutrition—Doxorubicin—sarcoma	7.97e-05	0.000985	CcSEcCtD
Mefloquine—Erythema—Doxorubicin—sarcoma	7.97e-05	0.000985	CcSEcCtD
Mefloquine—Agitation—Epirubicin—sarcoma	7.92e-05	0.000978	CcSEcCtD
Mefloquine—Rash—Etoposide—sarcoma	7.91e-05	0.000977	CcSEcCtD
Mefloquine—Dermatitis—Etoposide—sarcoma	7.9e-05	0.000976	CcSEcCtD
Mefloquine—Headache—Etoposide—sarcoma	7.86e-05	0.000971	CcSEcCtD
Mefloquine—Malaise—Epirubicin—sarcoma	7.77e-05	0.00096	CcSEcCtD
Mefloquine—Vertigo—Epirubicin—sarcoma	7.74e-05	0.000956	CcSEcCtD
Mefloquine—Syncope—Epirubicin—sarcoma	7.73e-05	0.000955	CcSEcCtD
Mefloquine—Leukopenia—Epirubicin—sarcoma	7.71e-05	0.000953	CcSEcCtD
Mefloquine—Muscle spasms—Doxorubicin—sarcoma	7.66e-05	0.000947	CcSEcCtD
Mefloquine—Palpitations—Epirubicin—sarcoma	7.61e-05	0.000941	CcSEcCtD
Mefloquine—Loss of consciousness—Epirubicin—sarcoma	7.57e-05	0.000936	CcSEcCtD
Mefloquine—Vision blurred—Doxorubicin—sarcoma	7.51e-05	0.000928	CcSEcCtD
Mefloquine—Convulsion—Epirubicin—sarcoma	7.47e-05	0.000922	CcSEcCtD
Mefloquine—ABCB1—testis—sarcoma	7.46e-05	0.000931	CbGeAlD
Mefloquine—Nausea—Etoposide—sarcoma	7.45e-05	0.000921	CcSEcCtD
Mefloquine—Hypertension—Epirubicin—sarcoma	7.44e-05	0.000919	CcSEcCtD
Mefloquine—ADORA2A—Signaling by NGF—FOXO1—sarcoma	7.43e-05	0.00128	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—PDGFRB—sarcoma	7.41e-05	0.00128	CbGpPWpGaD
Mefloquine—Ill-defined disorder—Doxorubicin—sarcoma	7.4e-05	0.000914	CcSEcCtD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KIT—sarcoma	7.36e-05	0.00127	CbGpPWpGaD
Mefloquine—Arthralgia—Epirubicin—sarcoma	7.34e-05	0.000906	CcSEcCtD
Mefloquine—Chest pain—Epirubicin—sarcoma	7.34e-05	0.000906	CcSEcCtD
Mefloquine—Myalgia—Epirubicin—sarcoma	7.34e-05	0.000906	CcSEcCtD
Mefloquine—Agitation—Doxorubicin—sarcoma	7.33e-05	0.000905	CcSEcCtD
Mefloquine—Anxiety—Epirubicin—sarcoma	7.31e-05	0.000903	CcSEcCtD
Mefloquine—ADORA2A—Signaling by NGF—PDGFRA—sarcoma	7.3e-05	0.00126	CbGpPWpGaD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	7.28e-05	0.0009	CcSEcCtD
Mefloquine—Discomfort—Epirubicin—sarcoma	7.25e-05	0.000895	CcSEcCtD
Mefloquine—BCHE—Peptide hormone metabolism—CTNNB1—sarcoma	7.23e-05	0.00124	CbGpPWpGaD
Mefloquine—Malaise—Doxorubicin—sarcoma	7.19e-05	0.000888	CcSEcCtD
Mefloquine—Vertigo—Doxorubicin—sarcoma	7.16e-05	0.000885	CcSEcCtD
Mefloquine—Syncope—Doxorubicin—sarcoma	7.15e-05	0.000883	CcSEcCtD
Mefloquine—ADORA2A—Circadian rythm related genes—CREB1—sarcoma	7.14e-05	0.00123	CbGpPWpGaD
Mefloquine—Leukopenia—Doxorubicin—sarcoma	7.14e-05	0.000882	CcSEcCtD
Mefloquine—ADORA2A—GPCR ligand binding—CXCR4—sarcoma	7.12e-05	0.00123	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—PDGFRA—sarcoma	7.1e-05	0.00122	CbGpPWpGaD
Mefloquine—Confusional state—Epirubicin—sarcoma	7.09e-05	0.000876	CcSEcCtD
Mefloquine—ABCB1—liver—sarcoma	7.05e-05	0.00088	CbGeAlD
Mefloquine—Palpitations—Doxorubicin—sarcoma	7.05e-05	0.00087	CcSEcCtD
Mefloquine—Anaphylactic shock—Epirubicin—sarcoma	7.03e-05	0.000869	CcSEcCtD
Mefloquine—Oedema—Epirubicin—sarcoma	7.03e-05	0.000869	CcSEcCtD
Mefloquine—Loss of consciousness—Doxorubicin—sarcoma	7.01e-05	0.000866	CcSEcCtD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—CREB1—sarcoma	7e-05	0.00121	CbGpPWpGaD
Mefloquine—Shock—Epirubicin—sarcoma	6.92e-05	0.000855	CcSEcCtD
Mefloquine—Convulsion—Doxorubicin—sarcoma	6.91e-05	0.000853	CcSEcCtD
Mefloquine—Nervous system disorder—Epirubicin—sarcoma	6.9e-05	0.000852	CcSEcCtD
Mefloquine—Thrombocytopenia—Epirubicin—sarcoma	6.88e-05	0.000851	CcSEcCtD
Mefloquine—Hypertension—Doxorubicin—sarcoma	6.88e-05	0.00085	CcSEcCtD
Mefloquine—Tachycardia—Epirubicin—sarcoma	6.86e-05	0.000848	CcSEcCtD
Mefloquine—Skin disorder—Epirubicin—sarcoma	6.83e-05	0.000844	CcSEcCtD
Mefloquine—Hyperhidrosis—Epirubicin—sarcoma	6.8e-05	0.00084	CcSEcCtD
Mefloquine—Arthralgia—Doxorubicin—sarcoma	6.79e-05	0.000839	CcSEcCtD
Mefloquine—Chest pain—Doxorubicin—sarcoma	6.79e-05	0.000839	CcSEcCtD
Mefloquine—Myalgia—Doxorubicin—sarcoma	6.79e-05	0.000839	CcSEcCtD
Mefloquine—Anxiety—Doxorubicin—sarcoma	6.76e-05	0.000836	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	6.74e-05	0.000833	CcSEcCtD
Mefloquine—Discomfort—Doxorubicin—sarcoma	6.71e-05	0.000829	CcSEcCtD
Mefloquine—ADORA1—Circadian rythm related genes—JUN—sarcoma	6.65e-05	0.00115	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	6.6e-05	0.00114	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—CREB1—sarcoma	6.59e-05	0.00113	CbGpPWpGaD
Mefloquine—Hypotension—Epirubicin—sarcoma	6.57e-05	0.000812	CcSEcCtD
Mefloquine—Confusional state—Doxorubicin—sarcoma	6.56e-05	0.000811	CcSEcCtD
Mefloquine—Oedema—Doxorubicin—sarcoma	6.51e-05	0.000804	CcSEcCtD
Mefloquine—Anaphylactic shock—Doxorubicin—sarcoma	6.51e-05	0.000804	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Epirubicin—sarcoma	6.41e-05	0.000792	CcSEcCtD
Mefloquine—Shock—Doxorubicin—sarcoma	6.4e-05	0.000791	CcSEcCtD
Mefloquine—Nervous system disorder—Doxorubicin—sarcoma	6.38e-05	0.000788	CcSEcCtD
Mefloquine—Thrombocytopenia—Doxorubicin—sarcoma	6.37e-05	0.000787	CcSEcCtD
Mefloquine—Insomnia—Epirubicin—sarcoma	6.36e-05	0.000786	CcSEcCtD
Mefloquine—Tachycardia—Doxorubicin—sarcoma	6.35e-05	0.000785	CcSEcCtD
Mefloquine—Skin disorder—Doxorubicin—sarcoma	6.32e-05	0.000781	CcSEcCtD
Mefloquine—Paraesthesia—Epirubicin—sarcoma	6.31e-05	0.00078	CcSEcCtD
Mefloquine—Hyperhidrosis—Doxorubicin—sarcoma	6.29e-05	0.000777	CcSEcCtD
Mefloquine—Dyspnoea—Epirubicin—sarcoma	6.27e-05	0.000775	CcSEcCtD
Mefloquine—Somnolence—Epirubicin—sarcoma	6.25e-05	0.000772	CcSEcCtD
Mefloquine—Dyspepsia—Epirubicin—sarcoma	6.19e-05	0.000765	CcSEcCtD
Mefloquine—Decreased appetite—Epirubicin—sarcoma	6.11e-05	0.000755	CcSEcCtD
Mefloquine—Hypotension—Doxorubicin—sarcoma	6.08e-05	0.000751	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Epirubicin—sarcoma	6.07e-05	0.00075	CcSEcCtD
Mefloquine—Fatigue—Epirubicin—sarcoma	6.06e-05	0.000749	CcSEcCtD
Mefloquine—ABCB1—HIF-1-alpha transcription factor network—CREB1—sarcoma	6.05e-05	0.00104	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	5.94e-05	0.00102	CbGpPWpGaD
Mefloquine—Musculoskeletal discomfort—Doxorubicin—sarcoma	5.93e-05	0.000732	CcSEcCtD
Mefloquine—Insomnia—Doxorubicin—sarcoma	5.88e-05	0.000727	CcSEcCtD
Mefloquine—Paraesthesia—Doxorubicin—sarcoma	5.84e-05	0.000722	CcSEcCtD
Mefloquine—Dyspnoea—Doxorubicin—sarcoma	5.8e-05	0.000717	CcSEcCtD
Mefloquine—Feeling abnormal—Epirubicin—sarcoma	5.79e-05	0.000716	CcSEcCtD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—MDM2—sarcoma	5.79e-05	0.000997	CbGpPWpGaD
Mefloquine—Somnolence—Doxorubicin—sarcoma	5.78e-05	0.000715	CcSEcCtD
Mefloquine—Gastrointestinal pain—Epirubicin—sarcoma	5.75e-05	0.00071	CcSEcCtD
Mefloquine—Dyspepsia—Doxorubicin—sarcoma	5.73e-05	0.000708	CcSEcCtD
Mefloquine—ACHE—Transmission across Chemical Synapses—CREB1—sarcoma	5.73e-05	0.000986	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—KIT—sarcoma	5.66e-05	0.000974	CbGpPWpGaD
Mefloquine—Decreased appetite—Doxorubicin—sarcoma	5.66e-05	0.000699	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Doxorubicin—sarcoma	5.62e-05	0.000694	CcSEcCtD
Mefloquine—Fatigue—Doxorubicin—sarcoma	5.61e-05	0.000693	CcSEcCtD
Mefloquine—Urticaria—Epirubicin—sarcoma	5.59e-05	0.00069	CcSEcCtD
Mefloquine—Abdominal pain—Epirubicin—sarcoma	5.56e-05	0.000687	CcSEcCtD
Mefloquine—Body temperature increased—Epirubicin—sarcoma	5.56e-05	0.000687	CcSEcCtD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—MDM2—sarcoma	5.45e-05	0.000938	CbGpPWpGaD
Mefloquine—ABCB1—lymph node—sarcoma	5.4e-05	0.000675	CbGeAlD
Mefloquine—ADORA2A—Signaling by NGF—CREB1—sarcoma	5.39e-05	0.000927	CbGpPWpGaD
Mefloquine—Feeling abnormal—Doxorubicin—sarcoma	5.36e-05	0.000662	CcSEcCtD
Mefloquine—Gastrointestinal pain—Doxorubicin—sarcoma	5.32e-05	0.000657	CcSEcCtD
Mefloquine—ADORA1—GPCR downstream signaling—CXCR4—sarcoma	5.21e-05	0.000898	CbGpPWpGaD
Mefloquine—Hypersensitivity—Epirubicin—sarcoma	5.18e-05	0.00064	CcSEcCtD
Mefloquine—Urticaria—Doxorubicin—sarcoma	5.17e-05	0.000639	CcSEcCtD
Mefloquine—Abdominal pain—Doxorubicin—sarcoma	5.14e-05	0.000636	CcSEcCtD
Mefloquine—Body temperature increased—Doxorubicin—sarcoma	5.14e-05	0.000636	CcSEcCtD
Mefloquine—ADORA2A—Circadian rythm related genes—JUN—sarcoma	5.14e-05	0.000884	CbGpPWpGaD
Mefloquine—BCHE—Transmission across Chemical Synapses—CREB1—sarcoma	5.11e-05	0.000879	CbGpPWpGaD
Mefloquine—Asthenia—Epirubicin—sarcoma	5.05e-05	0.000623	CcSEcCtD
Mefloquine—Pruritus—Epirubicin—sarcoma	4.97e-05	0.000615	CcSEcCtD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	4.92e-05	0.000846	CbGpPWpGaD
Mefloquine—Diarrhoea—Epirubicin—sarcoma	4.81e-05	0.000594	CcSEcCtD
Mefloquine—Hypersensitivity—Doxorubicin—sarcoma	4.79e-05	0.000592	CcSEcCtD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—CCND1—sarcoma	4.75e-05	0.000817	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—JUN—sarcoma	4.74e-05	0.000816	CbGpPWpGaD
Mefloquine—ACHE—Transmission across Chemical Synapses—MDM2—sarcoma	4.74e-05	0.000816	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—CXCR4—sarcoma	4.73e-05	0.000815	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—CTNNB1—sarcoma	4.7e-05	0.00081	CbGpPWpGaD
Mefloquine—Asthenia—Doxorubicin—sarcoma	4.67e-05	0.000577	CcSEcCtD
Mefloquine—Dizziness—Epirubicin—sarcoma	4.65e-05	0.000575	CcSEcCtD
Mefloquine—Pruritus—Doxorubicin—sarcoma	4.6e-05	0.000569	CcSEcCtD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—SRC—sarcoma	4.52e-05	0.000778	CbGpPWpGaD
Mefloquine—Vomiting—Epirubicin—sarcoma	4.47e-05	0.000552	CcSEcCtD
Mefloquine—ADORA2A—Signaling by NGF—MDM2—sarcoma	4.46e-05	0.000767	CbGpPWpGaD
Mefloquine—Diarrhoea—Doxorubicin—sarcoma	4.45e-05	0.00055	CcSEcCtD
Mefloquine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—sarcoma	4.44e-05	0.000764	CbGpPWpGaD
Mefloquine—Rash—Epirubicin—sarcoma	4.43e-05	0.000548	CcSEcCtD
Mefloquine—Dermatitis—Epirubicin—sarcoma	4.43e-05	0.000547	CcSEcCtD
Mefloquine—Headache—Epirubicin—sarcoma	4.41e-05	0.000544	CcSEcCtD
Mefloquine—ADORA1—Signaling Pathways—TLE1—sarcoma	4.39e-05	0.000756	CbGpPWpGaD
Mefloquine—ADORA1—Circadian rythm related genes—TP53—sarcoma	4.39e-05	0.000756	CbGpPWpGaD
Mefloquine—ACHE—Neuronal System—CREB1—sarcoma	4.39e-05	0.000755	CbGpPWpGaD
Mefloquine—ABCB1—HIF-1-alpha transcription factor network—JUN—sarcoma	4.35e-05	0.000749	CbGpPWpGaD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—NRAS—sarcoma	4.35e-05	0.000748	CbGpPWpGaD
Mefloquine—Dizziness—Doxorubicin—sarcoma	4.3e-05	0.000532	CcSEcCtD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	4.28e-05	0.000737	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	4.27e-05	0.000736	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	4.24e-05	0.00073	CbGpPWpGaD
Mefloquine—BCHE—Transmission across Chemical Synapses—MDM2—sarcoma	4.23e-05	0.000728	CbGpPWpGaD
Mefloquine—Nausea—Epirubicin—sarcoma	4.18e-05	0.000516	CcSEcCtD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—VEGFA—sarcoma	4.14e-05	0.000713	CbGpPWpGaD
Mefloquine—Vomiting—Doxorubicin—sarcoma	4.14e-05	0.000511	CcSEcCtD
Mefloquine—CYP3A4—Tryptophan metabolism—MDM2—sarcoma	4.12e-05	0.000709	CbGpPWpGaD
Mefloquine—Rash—Doxorubicin—sarcoma	4.1e-05	0.000507	CcSEcCtD
Mefloquine—Dermatitis—Doxorubicin—sarcoma	4.1e-05	0.000506	CcSEcCtD
Mefloquine—Headache—Doxorubicin—sarcoma	4.08e-05	0.000504	CcSEcCtD
Mefloquine—ADORA2A—GPCR downstream signaling—CXCR4—sarcoma	4.03e-05	0.000693	CbGpPWpGaD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGFR—sarcoma	3.96e-05	0.000682	CbGpPWpGaD
Mefloquine—BCHE—Neuronal System—CREB1—sarcoma	3.91e-05	0.000674	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—IL2—sarcoma	3.87e-05	0.000667	CbGpPWpGaD
Mefloquine—Nausea—Doxorubicin—sarcoma	3.86e-05	0.000478	CcSEcCtD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	3.83e-05	0.00066	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—MYC—sarcoma	3.81e-05	0.000656	CbGpPWpGaD
Mefloquine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—sarcoma	3.8e-05	0.000654	CbGpPWpGaD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KRAS—sarcoma	3.74e-05	0.000644	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	3.73e-05	0.000643	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—EGFR—sarcoma	3.73e-05	0.000641	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—VEGFC—sarcoma	3.7e-05	0.000638	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—CXCR4—sarcoma	3.66e-05	0.000629	CbGpPWpGaD
Mefloquine—ACHE—Neuronal System—MDM2—sarcoma	3.63e-05	0.000625	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—KRAS—sarcoma	3.52e-05	0.000606	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	3.5e-05	0.000603	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—SRC—sarcoma	3.47e-05	0.000598	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	3.43e-05	0.000591	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TLE1—sarcoma	3.39e-05	0.000584	CbGpPWpGaD
Mefloquine—ADORA2A—Circadian rythm related genes—TP53—sarcoma	3.39e-05	0.000584	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	3.36e-05	0.000578	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—NRAS—sarcoma	3.34e-05	0.000575	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—VEGFA—sarcoma	3.29e-05	0.000567	CbGpPWpGaD
Mefloquine—BCHE—Neuronal System—MDM2—sarcoma	3.24e-05	0.000558	CbGpPWpGaD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—HRAS—sarcoma	3.18e-05	0.000547	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	3.17e-05	0.000546	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—TP53—sarcoma	3.13e-05	0.000538	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—EGFR—sarcoma	3.05e-05	0.000524	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—FLT1—sarcoma	2.96e-05	0.00051	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PLCG1—sarcoma	2.91e-05	0.000501	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—KRAS—sarcoma	2.88e-05	0.000495	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—VEGFC—sarcoma	2.86e-05	0.000492	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	2.82e-05	0.000486	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CXCR4—sarcoma	2.8e-05	0.000481	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—ATF1—sarcoma	2.77e-05	0.000476	CbGpPWpGaD
Mefloquine—ACHE—Transmission across Chemical Synapses—HRAS—sarcoma	2.6e-05	0.000448	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	2.59e-05	0.000445	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—CREB1—sarcoma	2.54e-05	0.000437	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—ENO2—sarcoma	2.53e-05	0.000436	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—HBA1—sarcoma	2.51e-05	0.000433	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—HRAS—sarcoma	2.45e-05	0.000421	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—ENO2—sarcoma	2.33e-05	0.0004	CbGpPWpGaD
Mefloquine—BCHE—Transmission across Chemical Synapses—HRAS—sarcoma	2.32e-05	0.000399	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—HBA1—sarcoma	2.31e-05	0.000398	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—FLT1—sarcoma	2.29e-05	0.000394	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—ENO2—sarcoma	2.26e-05	0.000389	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PLCG1—sarcoma	2.25e-05	0.000387	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—HBA1—sarcoma	2.24e-05	0.000386	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—IGF1R—sarcoma	2.17e-05	0.000374	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CXCR4—sarcoma	2.16e-05	0.000372	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PLCG1—sarcoma	2.15e-05	0.00037	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	2.14e-05	0.000368	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—ATF1—sarcoma	2.14e-05	0.000368	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—FOXO1—sarcoma	2.07e-05	0.000356	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—IL2—sarcoma	2.06e-05	0.000355	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PDGFRB—sarcoma	2.06e-05	0.000355	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PDGFRA—sarcoma	2.03e-05	0.000349	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—MMP2—sarcoma	2e-05	0.000344	CbGpPWpGaD
Mefloquine—ACHE—Neuronal System—HRAS—sarcoma	1.99e-05	0.000343	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PLCG1—sarcoma	1.97e-05	0.00034	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—CREB1—sarcoma	1.96e-05	0.000337	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PLCG1—sarcoma	1.92e-05	0.00033	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—IL2—sarcoma	1.87e-05	0.000323	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	1.86e-05	0.000321	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	1.86e-05	0.00032	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	1.85e-05	0.000318	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—MMP2—sarcoma	1.78e-05	0.000306	CbGpPWpGaD
Mefloquine—BCHE—Neuronal System—HRAS—sarcoma	1.78e-05	0.000306	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—KDR—sarcoma	1.71e-05	0.000294	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IGF1R—sarcoma	1.68e-05	0.000288	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	1.67e-05	0.000287	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	1.62e-05	0.00028	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—FOXO1—sarcoma	1.59e-05	0.000275	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—IL2—sarcoma	1.59e-05	0.000274	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PDGFRB—sarcoma	1.59e-05	0.000274	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—KIT—sarcoma	1.57e-05	0.000271	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—NRAS—sarcoma	1.57e-05	0.000271	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PDGFRA—sarcoma	1.57e-05	0.00027	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—CTNNB1—sarcoma	1.53e-05	0.000263	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CREB1—sarcoma	1.5e-05	0.000258	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	1.5e-05	0.000257	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	1.46e-05	0.000252	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—IL2—sarcoma	1.45e-05	0.000249	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—EGFR—sarcoma	1.43e-05	0.000247	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	1.38e-05	0.000238	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—CTNNB1—sarcoma	1.36e-05	0.000235	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—KRAS—sarcoma	1.35e-05	0.000233	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—KDR—sarcoma	1.32e-05	0.000227	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MDM2—sarcoma	1.24e-05	0.000213	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	1.23e-05	0.000211	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—KIT—sarcoma	1.22e-05	0.000209	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—NRAS—sarcoma	1.22e-05	0.000209	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CREB1—sarcoma	1.16e-05	0.000199	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—HRAS—sarcoma	1.15e-05	0.000198	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—IL2—sarcoma	1.11e-05	0.000191	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—EGFR—sarcoma	1.11e-05	0.000191	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ENO2—sarcoma	1.1e-05	0.00019	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—HBA1—sarcoma	1.09e-05	0.000188	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CCND1—sarcoma	1.08e-05	0.000186	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—JUN—sarcoma	1.08e-05	0.000185	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CTNNB1—sarcoma	1.07e-05	0.000184	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—KRAS—sarcoma	1.05e-05	0.00018	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ENO2—sarcoma	1.04e-05	0.000179	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—HBA1—sarcoma	1.03e-05	0.000178	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—SRC—sarcoma	9.66e-06	0.000166	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MDM2—sarcoma	9.57e-06	0.000165	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—VEGFA—sarcoma	9.41e-06	0.000162	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PLCG1—sarcoma	9.35e-06	0.000161	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—NRAS—sarcoma	9.3e-06	0.00016	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—HRAS—sarcoma	8.89e-06	0.000153	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PLCG1—sarcoma	8.81e-06	0.000152	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MYC—sarcoma	8.66e-06	0.000149	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IL2—sarcoma	8.55e-06	0.000147	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—EGFR—sarcoma	8.47e-06	0.000146	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CCND1—sarcoma	8.34e-06	0.000144	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—JUN—sarcoma	8.32e-06	0.000143	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CTNNB1—sarcoma	8.26e-06	0.000142	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—KRAS—sarcoma	8e-06	0.000138	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—SRC—sarcoma	7.46e-06	0.000128	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—VEGFA—sarcoma	7.27e-06	0.000125	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—NRAS—sarcoma	7.18e-06	0.000124	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TP53—sarcoma	7.11e-06	0.000122	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—HRAS—sarcoma	6.8e-06	0.000117	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ENO2—sarcoma	6.79e-06	0.000117	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—HBA1—sarcoma	6.74e-06	0.000116	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MYC—sarcoma	6.69e-06	0.000115	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—EGFR—sarcoma	6.54e-06	0.000113	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—KRAS—sarcoma	6.18e-06	0.000106	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PLCG1—sarcoma	5.76e-06	9.91e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TP53—sarcoma	5.49e-06	9.45e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—HRAS—sarcoma	5.25e-06	9.04e-05	CbGpPWpGaD
